Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (LALEAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03917082
Recruitment Status : Recruiting
First Posted : April 16, 2019
Last Update Posted : December 9, 2020
Canadian Cancer Society (CCS)
NanoString Technologies, Inc.
Information provided by (Responsible Party):
Caroline Lohrisch, British Columbia Cancer Agency

Brief Summary:

Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis.

The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk of breast cancer; as determined by histopathologic criteria and confirmed by low risk genomic analysis using Prosigna®; will be safe and acceptable to this population, and will not compromise the expected excellent breast cancer specific outcomes for this population.

Condition or disease Intervention/treatment Phase
Breast Cancer Female Hormone Receptor Positive Tumor Drug: Tamoxifen Citrate Phase 2

Detailed Description:
Women older than 50 at diagnosis of an invasive breast cancer which is all of: node negative/N0i+; T1 or T2; low or intermediate grade; with strong or intermediate expression of hormone receptors (ER and PR); and HER2 negative, and who have had adequate local therapy for their tumor, are invited to participate in Prosigna® screening. A sample of their excised tumor is sent for Prosigna® testing. This is a validated and widely approved genomic test to assess recurrence risk in hormone receptor positive/HER2 negative, node negative breast tumors. Tumors with a low risk result, defined as Risk of Recurrence (ROR) less than or equal to 40, are then eligible for enrollment on the LA LEAST study of 2 years of endocrine therapy (tamoxifen for pre/perimenopausal women and aromatase inhibitor for postmenopausal women). To mimic real life, there is flexibility to switch to an alternate standard of care endocrine therapy during the two years if intolerable side effects develop. During the two years of therapy, participants are seen every six months and complete periodic quality of life (QOL) questionnaires designed to measure quality of life, mood, side effects, and anxiety/fear of recurrence. Following two years of therapy, participants have annual study visits until year 10, with similar questionnaires at some but not all time points, and assessment of study endpoints. Primary endpoint is the 5 year distant relapse free interval (DRFI), defined as freedom from distant recurrence or breast cancer death at five years. Secondary endpoints include longitudinal QOL comparisons, 10 year breast cancer free interval and 10 year contralateral breast cancer rate. It is anticipated that about 400 individuals will need to be screened to enroll 290 participants with requisite low score. The sample size is based on an expected 5 year DRFI of 96.8%, one sided alpha of 0.05 and a rejection of the alternate hypothesis if the lower boundary of the one sided confidence interval yields an observed DRFI below 95%.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 290 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single arm phase II study exploring reducing the duration of endocrine therapy from five to two years in low risk population with early breast cancer
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer
Actual Study Start Date : September 23, 2019
Estimated Primary Completion Date : May 1, 2026
Estimated Study Completion Date : May 1, 2029

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: standard of care endocrine therapy for two years
Standard of care adjuvant endocrine therapy for two years. for postmenopausal women, initial therapy will be aromatase inhibitor unless contraindicated, in which case tamoxifen may be used. For premenopausal and perimenopausal women, initial therapy will be tamoxifen unless contraindicated, in which case an lutenizing hormone releasing hormone (LHRH) agonist with / without aromatase inhibitor may be used.
Drug: Tamoxifen Citrate
current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
Other Name: aromatase inhibitor

Primary Outcome Measures :
  1. Distant Relapse Free Interval at five years [ Time Frame: 5 years after the last patient is enrolled ]
    freedom from distant recurrence or breast cancer death at 5 years

Secondary Outcome Measures :
  1. Ten year breast cancer free interval [ Time Frame: ten years after the last patient is enrolled ]
    freedom from local, regional, distant breast cancer recurrence or death from breast cancer or ipsilateral or contralateral ductal carcinoma in situ or contralateral invasive breast cancer at ten years

  2. Ten year contralateral breast cancer incidence [ Time Frame: ten years after the last patient is enrolled ]
    breast cancer occurring in the contralateral breast, including ductal carcinoma in situ (DCIS) and invasive breast cancer, within ten years of enrollment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   51 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   breast cancer incidence ratio in women vs men is 10:1. Given the sample size of the study, it is unlikely that enrolling men will provide any meaningful data about the impact of limited endocrine therapy for male breast cancer.
Accepts Healthy Volunteers:   No

Inclusion Criteria: for Prosigna® screening

  • Diagnosis of invasive breast cancer which is:

    • Unifocal or multifocal (not multicentric)
    • Unilateral
    • Moderate or strongly hormone receptor positive
    • HER2 negative
    • Ductal grade 1 or 2, or lobular any grade, or pure tubular (any grade) or pure papillary (any grade). If mixed lobular-ductal histology, the ductal component must be grade 1 or 2.
    • Stage pT1N0 (tumor </= 20mm, negative node) or pT2N0 (tumor 21-50mm, node negative) or pT1N0i+ (tumor </=20mm and isolated tumor cells in node[s]) or pT2N0i+ (tumor 21-50mm and isolated tumor cells in node[s]) (see Appendix 2). Tumor size must be sufficient for Prosigna® testing. pNX (nodal status unknown) stage is not eligible.
  • Subject must be female
  • Subject must be age > 50 years at breast cancer diagnosis
  • Subject may be pre, peri, or postmenopausal.
  • Subject must have a > 5-year life expectancy based on physician judgement of subject's co-morbid illnesses and age
  • Subject must undergo standard of care loco-regional management (sentinel node biopsy and/or axillary dissection; breast conserving surgery or mastectomy; radiation to breast following breast conserving surgery, with radiotherapy details per local institution practice). Surgery will have been no more than 24 weeks prior to endocrine therapy start. Subjects having repeat surgeries after radiation, regardless of indication, should count the date of last surgery that preceded radiation. Subjects may undergo Prosigna® screening prior to completion of radiation.
  • The breast surgery will have achieved negative surgical margins. Tumours with positive margins that are not re-resectable are eligible if followed by radiation with a boost (partial mastectomy) or chest wall radiation (mastectomy)
  • No (neoadjuvant or adjuvant) chemotherapy given or planned for this breast cancer
  • No other non-breast cancer within the last 5 years, except non-melanoma skin cancer, melanoma in situ, cervix carcinoma in situ, and anal carcinoma in situ
  • No prior hormone receptor positive invasive breast cancer. Prior contralateral DCIS treated with standard of care local therapy, and prior lobular carcinoma in situ (LCIS) are allowed, provided no endocrine therapy with any of tamoxifen, ovarian suppression, raloxifene, or aromatase inhibitor was given
  • Subject will have not have started endocrine therapy prior to enrollment
  • Subject has signed a screening informed consent form
  • Subject has intent to be adherent to endocrine therapy for two years in the absence of serious toxicity

Inclusion criteria for study enrollment:

  • Prosigna® score in the low risk range, defined as an ROR of 40 or lower
  • Subject has not yet initiated endocrine therapy
  • Subject has signed study informed consent form

Exclusion Criteria:

• Does not meet every inclusion criteria listed above

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03917082

Layout table for location contacts
Contact: Caroline Lohrisch, MD 6048776000 ext 2707

Layout table for location information
Canada, British Columbia
BC Cancer Recruiting
Vancouver, British Columbia, Canada, V5Z4E6
Contact: Caroline Lohrisch, MD    6048776000   
Sub-Investigator: Tamara Shenkier, MD         
Sub-Investigator: Stephen Chia, MD         
Sub-Investigator: Nathalie Levasseur, MD         
Sub-Investigator: Diego Villa, MD         
Sub-Investigator: Karen Gelmon, MD         
Sub-Investigator: Sophie Sun, MD         
Principal Investigator: Caroline Lohrisch, MD         
Sub-Investigator: Daniel Khalaf, MD         
Sub-Investigator: Christine Simmons, MD         
Sub-Investigator: Gary Pansegrau, MD         
Sponsors and Collaborators
British Columbia Cancer Agency
Canadian Cancer Society (CCS)
NanoString Technologies, Inc.
Layout table for investigator information
Study Chair: Caroline Lohrisch, MC BC Cancer

Layout table for additonal information
Responsible Party: Caroline Lohrisch, Medical Oncologist, Department head, medical oncology Vancouver Centre, British Columbia Cancer Agency Identifier: NCT03917082    
Other Study ID Numbers: LA LEAST
First Posted: April 16, 2019    Key Record Dates
Last Update Posted: December 9, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: summary results for participants will be shared in peer review meetings and publications

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Caroline Lohrisch, British Columbia Cancer Agency:
endocrine therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Aromatase Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors